Audentes Therapeutics Inc (BOLD)
followers
·
Follow
| Sector: | HEALTH CARE |
| Industry: | BIOTECHNOLOGY & LIFE SCIENCES |
| SIC: | BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) |
| CEO: | Matthew R. Patterson |
| Employees: | 207 |
| Web site: | www.audentestx.com |
|
600 CALIFORNIA ST., 17TH FLOOR, SAN FRANCISCO, CA, 94108
415-638-6556
| |
• *** This stock is shown as delisted in our database. *** If you think this isn't correct then please let us know
Are you looking for this stock instead?
| All 13F Filers | Prior | Change | Hedge Funds 1 | Prior | Change |
|---|
Audentes Therapeutics, Inc. is a biotechnology company, which engages on development and commercialization of gene therapy products for patients with serious and rare diseases caused by single gene defects. Its products include AT001 for the treatment of X-Linked Myotubular Myopathy, AT002 for the treatment of Pompe disease, and AT003 for the treatment of Catecholaminergic Polymorphic Ventricular Tachycardia. The company was founded by Matthew R. Patterson and Thomas J. Schuetz on November 13, 2012 and is headquartered in San Francisco, CA.
Please log in first to see chart